JP7757036B2 - Ｋｖ７チャネル活性化剤の構成および使用方法 - Google Patents

Ｋｖ７チャネル活性化剤の構成および使用方法

Info

Publication number
JP7757036B2
JP7757036B2 JP2020551340A JP2020551340A JP7757036B2 JP 7757036 B2 JP7757036 B2 JP 7757036B2 JP 2020551340 A JP2020551340 A JP 2020551340A JP 2020551340 A JP2020551340 A JP 2020551340A JP 7757036 B2 JP7757036 B2 JP 7757036B2
Authority
JP
Japan
Prior art keywords
isomers
alkyl
formula
optionally substituted
cor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020551340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518844A5 (enExample
JP2021518844A (ja
Inventor
イー． ボジック、マイケル
エス． ハリード、スコット
レズニック、リン
ティー． トパロブ、ジョージ
ケイ． ベラルディ、ジャスティン
エー． フレンジュ、チャールズ
エー． マレスカ、デイビッド
エス． ヘイル、ジェームズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of JP2021518844A publication Critical patent/JP2021518844A/ja
Publication of JP2021518844A5 publication Critical patent/JP2021518844A5/ja
Priority to JP2023195267A priority Critical patent/JP2024026104A/ja
Application granted granted Critical
Publication of JP7757036B2 publication Critical patent/JP7757036B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020551340A 2018-03-19 2019-03-19 Ｋｖ７チャネル活性化剤の構成および使用方法 Active JP7757036B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023195267A JP2024026104A (ja) 2018-03-19 2023-11-16 Ｋｖ７チャネル活性化剤の構成および使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862644932P 2018-03-19 2018-03-19
US201862644902P 2018-03-19 2018-03-19
US62/644,932 2018-03-19
US62/644,902 2018-03-19
US201862663438P 2018-04-27 2018-04-27
US62/663,438 2018-04-27
US201862697198P 2018-07-12 2018-07-12
US62/697,198 2018-07-12
PCT/US2019/023039 WO2019183148A1 (en) 2018-03-19 2019-03-19 Kv7 channel activators compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023195267A Division JP2024026104A (ja) 2018-03-19 2023-11-16 Ｋｖ７チャネル活性化剤の構成および使用方法

Publications (3)

Publication Number Publication Date
JP2021518844A JP2021518844A (ja) 2021-08-05
JP2021518844A5 JP2021518844A5 (enExample) 2023-01-06
JP7757036B2 true JP7757036B2 (ja) 2025-10-21

Family

ID=67905138

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551340A Active JP7757036B2 (ja) 2018-03-19 2019-03-19 Ｋｖ７チャネル活性化剤の構成および使用方法
JP2023195267A Pending JP2024026104A (ja) 2018-03-19 2023-11-16 Ｋｖ７チャネル活性化剤の構成および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023195267A Pending JP2024026104A (ja) 2018-03-19 2023-11-16 Ｋｖ７チャネル活性化剤の構成および使用方法

Country Status (13)

Country Link
US (5) US10851067B2 (enExample)
EP (1) EP3768677A4 (enExample)
JP (2) JP7757036B2 (enExample)
KR (3) KR20250150168A (enExample)
CN (6) CN119118926A (enExample)
AU (3) AU2019239955B2 (enExample)
BR (1) BR112020018933A2 (enExample)
CA (1) CA3093976A1 (enExample)
IL (2) IL277419B2 (enExample)
MX (2) MX2020009693A (enExample)
SG (1) SG11202008030WA (enExample)
WO (1) WO2019183148A1 (enExample)
ZA (1) ZA202308070B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2749103T3 (es) * 2014-09-12 2020-03-19 Knopp Biosciences Llc Benzoimidazol-1,2-ilamidas como activadores del canal Kv7
CN119118926A (zh) * 2018-03-19 2024-12-13 诺普生物科学有限责任公司 Kv7通道激活剂组合物和使用方法
IL328371A (en) * 2019-09-17 2026-07-01 Knopp Biosciences Llc Usage methods for KV7 channel operators
WO2023133256A1 (en) * 2022-01-07 2023-07-13 Biohaven Therapeutics Ltd. Pyrazolo[1,5-a]pyridin-2,3-yl amides as kv7 channel activators
WO2024050389A1 (en) * 2022-08-30 2024-03-07 Biohaven Therapeutics Ltd. Combination therapies including metal channel activators and nmda receptor antagonists
EP4584250A4 (en) * 2022-09-06 2026-02-25 Biohaven Therapeutics Ltd POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS
KR20260049605A (ko) * 2023-08-10 2026-04-14 바이오하벤 테라퓨틱스 리미티드 Kv7.2/7.3 칼륨 채널 활성제의 서방형 제형
KR20260074334A (ko) * 2023-09-15 2026-05-22 바이오하벤 테라퓨틱스 리미티드 강력하고 선택적인 칼륨 채널 활성제를 이용한 뇌전증 및 관련 질환의 치료 방법
KR20260114565A (ko) * 2023-11-15 2026-07-22 씨엠에스 리서치 앤드 디벨롭먼트 피티이. 리미티드 6,5-융합 헤테로아릴 유도체 및 이의 용도
CN122421958A (zh) * 2023-12-22 2026-07-17 拜奥海芬治疗学有限公司 神经性障碍的组合治疗
WO2025198930A1 (en) * 2024-03-18 2025-09-25 Humanwell Pharmacuetical Us, Inc. Small molecules as kcnq2/3 (kv7.2/3) channel activators and their medical use thereof
WO2026042005A1 (en) 2024-08-18 2026-02-26 Biohaven Therapeutics Ltd. Prodrugs of benzimidazol-1,2-yl amide compounds
WO2026046157A1 (zh) * 2024-08-27 2026-03-05 上海汇伦医药股份有限公司 苯并杂芳环类化合物、含其的组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160075663A1 (en) 2014-09-12 2016-03-17 Knopp Biosciences Llc BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0772181B2 (ja) 1989-06-26 1995-08-02 株式会社大塚製薬工場 ベンズイミダゾール誘導体
JPH0772181A (ja) 1993-09-03 1995-03-17 Advantest Corp 電位波形測定方法および装置
GB9413724D0 (en) 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
CA2607219A1 (en) 2005-05-18 2007-02-15 Neuraxon, Inc. Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
US8288393B2 (en) 2007-08-10 2012-10-16 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and pest control agent
EP2218718A1 (en) 2007-11-22 2010-08-18 Zenyaku Kogyo Kabushikikaisha Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same
GB0723794D0 (en) 2007-12-05 2008-01-16 Lectus Therapeutics Ltd Potassium ion channel modulators and uses thereof
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
US20110269783A1 (en) 2008-11-10 2011-11-03 Neurosearch A/S Novel 2,3-diamino-quinazolinone derivatives and their medical use
KR101685718B1 (ko) 2008-12-19 2016-12-12 제넨테크, 인크. 헤테로시클릭 화합물 및 사용 방법
US8883812B2 (en) 2010-07-08 2014-11-11 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
SG10201505997TA (en) 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
WO2014145852A2 (en) * 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
US10471139B2 (en) * 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
CN119118926A (zh) * 2018-03-19 2024-12-13 诺普生物科学有限责任公司 Kv7通道激活剂组合物和使用方法
IL328371A (en) * 2019-09-17 2026-07-01 Knopp Biosciences Llc Usage methods for KV7 channel operators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160075663A1 (en) 2014-09-12 2016-03-17 Knopp Biosciences Llc BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS
US20170114022A1 (en) 2014-09-12 2017-04-27 Knopp Biosciences Llc BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PubChem，Created：2017年8月4日，検索日：2023年3月15日，CID 129064862

Also Published As

Publication number Publication date
SG11202008030WA (en) 2020-10-29
CN119118926A (zh) 2024-12-13
KR102868652B1 (ko) 2025-10-13
KR20200133259A (ko) 2020-11-26
US20210130299A1 (en) 2021-05-06
IL277419B1 (en) 2024-03-01
US20230000831A1 (en) 2023-01-05
CA3093976A1 (en) 2019-09-26
US11261162B2 (en) 2022-03-01
CN112771039A (zh) 2021-05-07
BR112020018933A2 (pt) 2020-12-29
CN118955401A (zh) 2024-11-15
JP2024026104A (ja) 2024-02-28
US20190284142A1 (en) 2019-09-19
AU2019239955B2 (en) 2023-08-24
ZA202308070B (en) 2025-04-30
AU2023266373B2 (en) 2024-02-08
AU2024202496A1 (en) 2024-05-09
KR20240163771A (ko) 2024-11-19
WO2019183148A1 (en) 2019-09-26
KR102731128B1 (ko) 2024-11-18
EP3768677A4 (en) 2021-12-22
AU2024202496B2 (en) 2026-05-28
US20240002349A1 (en) 2024-01-04
EP3768677A1 (en) 2021-01-27
AU2019239955A1 (en) 2020-10-01
JP2021518844A (ja) 2021-08-05
US11724990B2 (en) 2023-08-15
US20260062389A1 (en) 2026-03-05
CN118955400A (zh) 2024-11-15
IL277419A (en) 2020-11-30
IL310136A (en) 2024-03-01
NZ767228A (en) 2023-11-24
CN118955403A (zh) 2024-11-15
KR20250150168A (ko) 2025-10-17
MX2020009693A (es) 2021-01-08
IL277419B2 (en) 2024-07-01
US12286408B2 (en) 2025-04-29
CN118955402A (zh) 2024-11-15
AU2023266373A1 (en) 2023-12-07
MX2023001153A (es) 2023-02-22
US10851067B2 (en) 2020-12-01

Similar Documents

Publication Publication Date Title
KR102868652B1 (ko) Kv7 채널 활성화제 조성물 및 이의 사용 방법
US20070225316A1 (en) Methods and compositions for treating schizophrenia
TW202028180A (zh) 作為神經元組織胺受體－３拮抗劑之化合物及其用途
WO2023164538A1 (en) Pyrazolyl compounds as kv7 channel activators
HK40119318A (en) Kv7 channel activators compositions and methods of use
HK40118422A (en) Kv7 channel activators compositions and methods of use
HK40119317A (en) Kv7 channel activators compositions and methods of use
HK40120047A (en) Kv7 channel activators compositions and methods of use
HK40119631A (en) Kv7 channel activators compositions and methods of use
CN118678954A (zh) 作为kv7通道激活剂的吡唑基化合物
JP2025502536A (ja) Ｍ－コリン受容体アゴニスト化合物及びその製造方法並びに使用
WO2017151006A1 (ru) Фармацевтическая композиция для лечения функциональных психических расстройств

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20221205

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231214

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240222

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251008

R150 Certificate of patent or registration of utility model

Ref document number: 7757036

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150